bucillamine / Revive Therap, Supriya Lifesci - LARVOL DELTA

Bucillamine-induced Yellow Nail Syndrome with Chylothorax: A Case Report. (PubMed, Intern Med) - "The chylothorax persisted despite the discontinuation of bucillamine. The present case illustrates that bucillamine can cause irreversible lymphatic impairment and chylothorax."

Journal • Inflammation • Respiratory Diseases

Bucillamine-induced membranous nephropathy versus primary membranous nephropathy: comparing pathological features and kidney prognosis. (PubMed, Sci Rep) - "Clinically, the majority of patients in the BCL-MN group experienced proteinuria resolution after 1 year of drug discontinuation alone, and there was no progression of renal function decline. BCL-MN differs from p-MN both histologically and clinically, which may be related to the mechanism induced by BCL."

Journal • Glomerulonephritis • Immunology • Inflammatory Arthritis • Renal Disease • Rheumatoid Arthritis • Rheumatology

NELL1-Positive Membranous Nephropathy in Renal Allografts: A Series of Six Patients. (PubMed, Am J Transplant) - "None of the patients in this series had known triggers of MN, such as malignancy or associated medications (including lipoic acid, bucillamine, tiotropin, or indigenous medicines). This suggests that NELL1, though not a podocyte antigen, may present as an idiopathic disease or transplantation may serve as an exposure for the development of NELL1+ MN."

Journal • Glomerulonephritis • Nephrology • Oncology • Renal Disease • Transplantation • EGF • NELL1

Pharmaceutical Interventions for the Management of Hemorrhagic Shock in Hepatic Surgery: An Experimental Swine Model Outcome. (PubMed, Cureus) - "This study examines the effectiveness of combining standard fluid therapy with antioxidants (bucillamine and valproic acid) in mitigating oxidative stress and reducing hepatocyte damage in the context of hemorrhagic shock.  Method Thirty male swine were randomly divided into four groups as follows: Group A (n=6/control group), Group B (n=8), Group C (n=8), and Group D (n=8)...Conclusion These findings suggest that incorporating antioxidant therapy into resuscitation protocols may offer substantial benefits in mitigating hepatic damage associated with hemorrhagic shock. This approach could potentially improve outcomes in clinical settings where oxidative stress plays a critical role in injury progression by better understanding the pathophysiology of this complex and dynamic process."

Journal • Surgery • Cardiovascular • Hematological Disorders • Hepatology • Reperfusion Injury

Clinicopathological characteristics of neural epidermal growth factor-like 1 protein-associated membranous glomerulonephritis. (PubMed, Virchows Arch) - "The characteristic histological feature of segmental distribution in NELL1-positive MGN may be related to bucillamine use and the early phase of the disease. Further investigations with larger numbers of patients may offer further insight into the prognosis of patients with NELL1-positive MGN."

Journal • CNS Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Psychiatry • EGF • NELL1

NELL1 membranous nephropathy: clinical associations provide mechanistic clues. (PubMed, Front Nephrol) - "It has been associated with a variety of exposures and secondary conditions, specifically use of thiol-containing medications - including lipoic acid, bucillamine, and tiopronin - as well as traditional indigenous medications (TIM) particularly those with high mercury content, and non-steroid anti-inflammatory drugs (NSAIDs)...Genome-wide association study of NELL1, role of NELL1 in other physiologic and pathologic processes, and connection between NELL1 MN and malignancy with relevance of NELL1 tumor staining are examined. Finally, relationships and potential disease mechanisms of thiol- and mercury- associated NELL1 MN are discussed."

Journal • Review • Glomerulonephritis • Graft versus Host Disease • Immunology • Infectious Disease • Nephrology • Oncology • Psychiatry • Renal Disease • NELL1

Lymphoproliferative disorder progressing after partial remission following immunosuppressive drugs withdrawal in a patient with rheumatoid arthritis. (PubMed, Mod Rheumatol Case Rep) - "Here, we report a 73-year-old woman was diagnosed with RA at 60 years of age and treated with methotrexate, bucillamine, prednisolone, and infliximab...After pulse steroid therapy, the patient received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy, which resulted in a complete response. In conclusion, when LPDs develop in patients with RA during ISD treatment, LPDs can progress and complicate HPS after partial remission following ISDs withdrawal. Therefore, we should carefully follow up RA patients with LPDs, aim to achieve an early diagnosis of LPD, and promptly initiate chemotherapy."

Journal • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Rheumatoid Arthritis • Rheumatology

Oral intake of bucillamine, carvedilol, metformin, or phenformin does not protect against UVR-induced squamous cell carcinomas in hairless mice. (PubMed, Photochem Photobiol Sci) - "Metformin treatment significantly reduced UVR-induced erythema (P = 0.012), bucillamine and phenformin increased dorsal pigmentation (P = 0.0013, and P = 0.0005), but no other photoprotective effect was observed across the repurposed groups. This study demonstrates that oral supplementation with bucillamine, carvedilol, metformin, or phenformin does not affect UVR-induced carcinogenesis in hairless mice."

Journal • Preclinical • Dermatology • Genetic Disorders • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Squamous Cell Carcinoma

Dual stimuli-responsive and sustained drug delivery NanoSensoGel formulation for prevention of cisplatin-induced ototoxicity. (PubMed, J Control Release) - "Cisplatin (CisPt)-induced ototoxicity (CIO) is delineated as a consequence of CisPt-induced intracellular generation of reactive oxygens species (ROS) which can be circumvented by Bucillamine (BUC; an antioxidant drug with sulfhydryl groups) and Diltiazem (DLT, L-type calcium channel blocker). The NanoSensoGel showed sustained release of BUC and DLT following Fickian release diffusion kinetics determined using the Korsmeyer-Peppas model. Overall, a novel NanoSensoGel formulation has demonstrated its great potential in delivering therapeutics in the inner ear for prophylactic treatment of CIO, and associated hearing loss."

Journal • Otorhinolaryngology • CASP3 • CASP7

Response to Letter to the Editor entitled "Adding Cases to the Study of Bucillamine-Associated Neural Epidermal Growth Factor Like1-Positive Membranous Nephropathy". (PubMed, Kidney Int Rep) - No abstract available

Journal • Glomerulonephritis • Renal Disease

Adding Cases to the Study of Bucillamine-Associated Neural Epidermal Growth Factor-Like1-Positive Membranous Nephropathy. (PubMed, Kidney Int Rep) - No abstract available

Journal • Glomerulonephritis • Renal Disease

Chiral discrimination of cyclodecapeptide to anti-COVID-19 clinical candidates: a theoretical study. (PubMed, Struct Chem) - "In this work, we employed cyclic decapeptide as the host molecule and the M06-2X theoretical computational method for chiral recognition of four clinical candidate guests and their isomers, including bucillamine, molnupiravir, azvudine, and VV116, which are relevant for the treatment of COVID-19. These findings might provide a theoretical reference for the identification and separation of chiral compounds in host-guest interaction. The online version contains supplementary material available at 10.1007/s11224-023-02149-5."

Journal • Infectious Disease • Novel Coronavirus Disease

Bucillamine in Treatment of Patients With COVID-19 (clinicaltrials.gov) - P3 | N=695 | Terminated | Sponsor: Revive Therapeutics, Ltd. | N=1000 ➔ 695 | Trial completion date: Dec 2022 ➔ Jun 2023 | Enrolling by invitation ➔ Terminated | Trial primary completion date: Dec 2022 ➔ Jun 2023; Met definition of futility according to DSMB

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients. (PubMed, Rheumatology (Oxford)) - "Repeated vaccinations in many immunosuppressed patients produced antibody responses similar to those observed in HCs. In contrast, annual vaccination in patients receiving TNF inhibitors, abatacept, mycophenolate mofetil and rituximab may require caution."

Journal • Immunology • Infectious Disease • Inflammatory Arthritis • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • IL6

Neural Epidermal Growth Factor-Like 1-Positive Membranous Nephropathy With Rheumatoid Arthritis. (PubMed, Kidney Int Rep) - No abstract available

Journal • Glomerulonephritis • Immunology • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatoid Arthritis • Rheumatology

"#bucillamine has great potential to treat covid! https://t.co/7z2IIUswuH" (@kindmafia11111)

Novel Coronavirus Disease

Investigation of Bucillamine as anti-COVID-19 drug: DFT study, molecular docking, molecular dynamic simulation and ADMET analysis. (PubMed, J Biomol Struct Dyn) - "Finally, an in silico study was performed to predict drug-likeness and absorption, distribution, metabolism, excretion and toxicity profiles (ADMET) of BUC. These results propose that BUC can be a potential drug candidate against the COVID-19 disease progression.Communicated by Ramaswamy H. Sarma."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A LIMITED BIOPSY REVEALS AN UNCOMMON COMBINATION: MEMBRANOUS NEPHROPATHY AND AA AMYLOIDOSIS (ISN-WCN 2023) - "Membranous nephropathy in Rheumatoid Arthritis (RA) was mainly secondary to the use of gold salts, penicillamine, or bucillamine...Cases still occur in association and may be due circulating autoantibodies in RA targeting some podocyte protein. Rheumatoid arthritis or juvenile idiopathic arthritis are reported to underlie AA amyloidosis in 12-21% of cases in the United States and is related to duration of the disease activity, greater disability, and higher levels of inflammation."

Biopsy • Acute Kidney Injury • Amyloidosis • Atrial Fibrillation • Cardiovascular • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Dyslipidemia • Endocrine Disorders • Fatigue • Glomerulonephritis • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Metabolic Disorders • Nephrology • Oncology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Sarcoidosis • Systemic Lupus Erythematosus

"@US_FDA help @Revive_RVV get #BUCILLAMINE developed faster to reduce inflammation" (@Renita232323)

Inflammation

"Tuesday, March 7th - come & gone .. It's OK, we got used to WAITING - for a Positive Outcome (OMG, how many years NOW !!) #Bucillamine $RVV $RVVTF @Revive_RVV @US_FDA #USFDA @DrCaliff_FDA" (@ravirav83820646)

Bucillamine in Treatment of Patients With COVID-19 (clinicaltrials.gov) - P3 | N=1000 | Enrolling by invitation | Sponsor: Revive Therapeutics, Ltd. | Trial completion date: Jun 2022 ➔ Dec 2022 | Trial primary completion date: Jun 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

"GAME CHANGER ALERT 🚨 💴💴@Revive_RVV #BUCILLAMINE $RVV $RVVTF @pfizer @Merck @CBCAlerts @NBCNews @WHO @BARDA #COVID19 #CovidIsNotOver https://t.co/PzBisyvXQv" (@Chrissd41)

Infectious Disease • Novel Coronavirus Disease

"Bucillamine results?" (@FrancsRant)

"Time to buy is now!!! #BUCILLAMINE $RVV $RVVTF @Revive_RVV @MWekerle @pfizer @Merck @AstraZeneca 🤑🤑🚀🚀" (@Chrissd41)

"I like that it states "Special Meeting" can wait, goods things to come... #bucillamine $rvv $rvvtf @POTUS @US_FDA @DrTedros @JustinTrudeau @HealthCanada3" (@mactwo2013)

Canadian regulatory